Find out how many vaccine doses have been given in your country using WHO’s COVID-19 dashboard
Rabies is a vaccine-preventable viral disease which occurs in more than 150 countries and territories. Dogs are the source of the vast majority of human rabies deaths, contributing up to 99% of all rabies transmissions to humans.
Rabies is a vaccine-preventable, zoonotic, viral disease affecting the central nervous system. Once clinical symptoms appear, rabies is virtually 100% fatal. In up to 99% of cases, domestic dogs are responsible for rabies virus transmission to humans. Yet, rabies can affect both domestic and wild an...imals. It spreads to people and animals via saliva, usually through bites, scratches or direct contact with mucosa (e.g. eyes, mouth or open wounds). Children between the age of 5 and 14 years are frequent victims.
more
Child and adolescent vaccine safety report
This report on the safety of COVID-19 vaccination in children and adolescents in Argentina includes data from the start of the adolescent campaign
in Argentina, includes data reported since the start of the campaign in adolescents (28 July 2021) and in ch...ildren aged 3-11 years (12 October 2021) until 6 AM on 31 October 2021.
more
Guidelines for Handling Temperature Sensitive Vaccines and Pharmaceuticals
PHARMA’S RESPONSE TO THE COVID-19 VACCINES CRISIS. Update Feb., 14, 2022. In September 2021, Amnesty International published A Double Dose of Inequality, which assessed the extent to which the pharmaceutical industry was restricting access to Covid-19 vaccines. This report updates that assessment ...of five leading vaccine manufacturers, AstraZeneca plc, BioNTech SE, Johnson & Johnson, Moderna Inc., and Pfizer Inc. It also includes for the first time an assessment of the two largest Chinese vaccine producers, China National Pharmaceutical Group Co., Ltd. (Sinopharm) and Sinovac Biotech Ltd. (Sinovac).
more
Position paper on vaccination with Sputnik V vaccine | National Commission on Vaccine Safety (CoNaSeVa) | 12 May 2021
Evaluation of the effectiveness of vaccines against COVID-19
INTERIM GUIDANCE 17 MARCH 2021
WHO lists 9th COVID-19 vaccine for emergency use to expand vaccination access in low-income countries, 17 December 2021
Sierra Leone Trial to Introduce a Vaccine against Ebola (STRIVE)
National Operationalisation Plan for the COVID-19 Vaccine : 13th edition
In the current absence of vaccine for COVID-19, public health response target breaking the chain of infection by focusing on the mode of transmission. This paper summarizes current evidence-base around the transmission dynamics, pathogenic, and clinical features of COVID-19, to critically identify i...f there are any gaps in the current IPC guidelines.
more
These organisations have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly for low- and middle-income countries.
The aim is to vaccinate at least 40 percent of people in every country by the end... of 2021, and at least 60 percent by mid-2022. The effort will track, coordinate, and advance delivery of COVID-19 vaccines, therapeutics and diagnostics, working with governments and partners at the global and local levels to address finance and trade barriers to ensure that vulnerable populations have access to these life-saving tools. It supports the goals of the ACT-Accelerator and complementary initiatives.
more
Rabies is a public health problem in Asia and vaccine affordability is an issue.
There is no reduction in the number of persons seeking post-exposure prophylaxis.
The high cost of cell culture vaccines for intramuscular use is a limiting factor.
Intradermal rabies vaccination offers cost-effectiv...e alternative to intramuscular.
WHO recommended one week intradermal schedule will ensure good patient compliance.
more
As of January 20, 2021 the Covid-19 - living NMA initiative collected 150 RCTs and 36 non-randomised studies of vaccines from the ICTRP. 93 of these trials are recruiting patients.
This guide is intended to support national governments developing their national deployment and vaccination plans (NDVPs) for COVID-19 vaccines by outlining the roles, needs and opportunities for community health workers (CHWs) to contribute. This note builds on and is structured to align with the G...uidance on developing a national deployment and vaccination plan for COVID-19 vaccines. By providing CHW-relevant considerations for the VIRAT Tool, this document aims to support national governments in developing robust NDVPs for introducing COVID-19 vaccine(s) that leverage all the community-based deployment, implementation and monitoring tools at their disposal.
more
Immunizations are an essential health service that protect susceptible individuals from vaccine-preventable diseases (VPD).2 By providing timely immunizations, individuals and communities remain protected and the likelihood of a VPD outbreak decreases
This publication is available in Arabic, Chines...e, English, French, Russian and Spanish
more
The backsliding of immunization coverage during the COVID-19 pandemic, combined with delayed catch-up efforts has resulted in a large and growing immunity gap. There is an urgent need to close this gap, and enable millions of missed children to be vaccinated. The Essential Immunization Recovery Plan... sets out a path to getting immunization back on track, framed by three key approaches – Catch-Up, Restore and Strengthen. This document serves as the joint strategic description of this coordinated effort by WHO, UNICEF, and Gavi, the Vaccine Alliance, along with the Immunization Agenda 2030 (IA2030) Partnership, to support countries to plan and implement intensified efforts to bolster immunization programmes in 2023 and beyond.
more
Immunization is one of the most cost-effective public health interventions to date, saving an estimated 2 to 3 million lives each year. As a direct result of immunization, the world is closer than ever to eradicating polio, and deaths from measles – a major child killer – have declined by 73 per... cent worldwide between 2000 and 2018, saving an estimated 23.2 million children’s lives. The emergence of COVID-19, however, threatens to reverse this progress by severely limiting access to life-saving vaccines.
more
Introduction Pharmacovigilance (PV) systems to monitor drug and vaccine safety are often inadequate in sub-Saharan
Africa. In Malawi, a PV enhancement initiative was introduced to address major barriers to PV.
Objective The objective of this initiative was to improve reporting of adverse events (A...Es) by strengthening passive safety
surveillance via PV training and mentoring of local PV stakeholders and healthcare providers (HCPs) at their own healthcare
facilities (HCFs).
Methods An 18-month PV training and mentoring programme was implemented in collaboration with national stakeholders,
and in partnership with the Ministry of Health, GSK and PATH. Two-day training was provided to Expanded Programme on
Immunisation coordinators, identified as responsible for AE reporting, and four National Regulatory Authority representa-
tives. Abridged PV training and mentoring were provided regularly to HCPs. Support was given in upgrading the national
PV system. Key performance indicators included the number of AEs reported, transmission of AE forms, completeness of
reports, serious AEs reported and timeliness of recording into VigiFlow.
Results In 18 months, 443 HCPs at 61 HCFs were trained. The number of reported AEs increased from 22 (January 2000 to
October 2016) to 228 (November 2016 to May 2018), enabling Malawi to become a member of the World Health Organization
Programme for International Drug Monitoring. Most (98%) AE report forms contained mandatory information on reporter,
event, patient and product, but under 1% were transmitted to the national PV office within 48 h.
Conclusion Regular PV training and mentoring of HCPs were effective in enhancing passive safety surveillance in Malawi,
but the transmission of reports to the national PV centre requires further improvement.
more